Weight Loss News and Research

Latest Weight Loss News and Research

Burger, fries and a statin please!

British scientists have come up with a novel idea. They suggested that junk food counters should hand out free cholesterol-lowering statin drugs to their customers to “neutralize” the heart risks of eating fatty foods like burgers and fries. The idea is to project having high cholesterol fatty food as risky a behavior as driving or smoking that needs the user to go for seatbelts and filtered cigarettes respectively.

17 Aug 2010

Bariatric surgery can result in sustained reversal of obesity, type 2 diabetes: Study

Results of a large national study show that nearly three-quarters of obese patients with type 2 diabetes who undergo weight-loss surgery are able to stop insulin and other antidiabetes drugs within six months. In the Johns Hopkins study of insured, obese, diabetic patients, researchers also found that in the third year following surgery, average annual health care costs per patient decreased by more than 70 percent. The study is published in the Archives of Surgery this month.

17 Aug 2010

Smart for Life continues to improve Chocolate Chip Cookie

The trailblazing company whose Smart for Life weight management products featuring the cookie diet component has recently improved its Chocolate Chip Cookie to include the most protein offered in a meal replacement cookie on the market at a whopping 6 grams per serving. The amount of protein found in meal replacements is instrumental in curbing hunger, maintaining muscle mass, and providing energy, not to mention contributing to weight loss.

16 Aug 2010

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Shire plc, the global specialty biopharmaceutical company, announced the divestiture of Daytrana (methylphenidate transdermal system) to Noven Pharmaceuticals, Inc. Daytrana, which is approved and marketed in the US for the treatment of Attention Deficit Hyperactivity Disorder in children and adolescents, will continue to be available for patients through Noven.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of treatment, consistent with previous analyses.

10 Aug 2010

Sleeve gastrectomy for weight loss surgery with no scars

Surgeons at the University of California, San Diego School of Medicine have achieved what is believed to be the nation's first stomach reduction via the mouth. The novel weight loss procedure, known as a sleeve gastrectomy, reduces the stomach to 20 percent of its original size. The smaller stomach leads to less caloric intake and increased feelings of fullness. This is the first time in the U.S. that the excess stomach has been removed through the mouth rather than a large open incision.

10 Aug 2010

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

BioVentrix announces First-in-Man milestone for PliCath heart failure system

BioVentrix, developer of the PliCath HF™ System for use in Epicardial Catheter-based Ventricular Reconstruction (ECVR), today announced achievement of its First-in-Man milestone, performed on a 52-year-old male heart failure patient in Krakow, Poland. The PliCath HF System is designed to treat heart failure (HF) by reducing the enlarged Left Ventricle (LV) through an anchoring system that is delivered across the cardiac chambers with the use of a catheter.

9 Aug 2010

Orexigen second-quarter net loss decreases to $11.9 million

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2010. For the quarter ended June 30, 2010, Orexigen reported a net loss of $11.9 million, or $0.25 per share attributable to common stockholders, as compared to a net loss of $17.8 million, or $0.51 per share attributable to common stockholders, for the second quarter of 2009.

7 Aug 2010

FDA confirms Advisory Committee meeting date for lorcaserin NDA review

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified the company of the confirmed scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 16, 2010, for the review of the lorcaserin New Drug Application (NDA). Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

7 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Studies show biological agents play important role in maintaining remission in Crohn's disease

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association Institute.

6 Aug 2010

Medifast net revenue for second-quarter 2010 increases 60% to $66.7 million

Medifast, Inc., a leading provider of clinically proven portion-controlled weight-loss programs, today reported financial results for the second quarter ended June 30, 2010.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Contrave added to diet and exercise regimen can induce significant weight loss

Orexigen Therapeutics, Inc. announced the online publication of results from its COR-BMOD trial of Contrave (naltrexone SR/bupropion SR) in the journal Obesity. The COR-BMOD trial evaluated intensive behavior modification plus Contrave32 (32mg naltrexone sustained release (SR)/360mg bupropion SR) compared to BMOD plus placebo, in 793 overweight or obese patients.

4 Aug 2010

Arena reports lower net loss of $28.80M for second-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2010, and recent developments, including the successful Pre-Approval Inspection, or PAI, of the company's Swiss drug product manufacturing facility by the US Food and Drug Administration, or FDA.

4 Aug 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

A study by researchers at NYU Langone Medical Center have found that obese adolescents with type 2 diabetes have diminished cognitive performance and subtle abnormalities in the brain as detected by Magnetic Resonance Imaging (MRI). Identification of cognitive impairments as a complication of type 2 diabetes emphasizes the importance of addressing issues of inactivity and obesity, two important risk factors for the development of the disease among the young.

3 Aug 2010

Study finds low carbohydrate diet may help improve cardiovascular risk factors

The effectiveness of a low-carbohydrate diet versus a low-fat diet for weight loss have been frequently debated. According to a new study published in Annals of Internal Medicine, both diets produce identical weight loss when coupled with comprehensive behavior treatment, but a low-carbohydrate diet may help improve cardiovascular risk factors.

3 Aug 2010

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS, Inc., a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the second quarter and six months ended June 30, 2010.

3 Aug 2010

Weight Loss News and Research

Latest Weight Loss News and Research

Burger, fries and a statin please!

Bariatric surgery can result in sustained reversal of obesity, type 2 diabetes: Study

Smart for Life continues to improve Chocolate Chip Cookie

Shire announces divestiture of Daytrana to Noven Pharmaceuticals

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting

Sleeve gastrectomy for weight loss surgery with no scars

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

BioVentrix announces First-in-Man milestone for PliCath heart failure system

Orexigen second-quarter net loss decreases to $11.9 million

FDA confirms Advisory Committee meeting date for lorcaserin NDA review

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Studies show biological agents play important role in maintaining remission in Crohn's disease

Medifast net revenue for second-quarter 2010 increases 60% to $66.7 million

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Contrave added to diet and exercise regimen can induce significant weight loss

Arena reports lower net loss of $28.80M for second-quarter 2010

Insulin resistance from obesity leads to lower cognitive performance in children: Research

Study finds low carbohydrate diet may help improve cardiovascular risk factors

VIVUS second-quarter total revenue decreases to $3.9 million

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Weight Loss News and Research

Latest Weight Loss News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in